Intercell AG

euro adhoc: Intercell AG
Restructuring & Recapitalisations
Intercell AG: Over-allotment option fully exercised

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@


Intercell announced today that Merrill Lynch International, the underwriter of its recent public offering of common shares, has exercised in full the over-allotment option which was granted by the selling shareholders.  The over-allotment comprised of 1,142,848 existing shares of common stock which were placed at the offer price of EUR 12.36.  Following the exercise of the over-allotment option, the gross proceeds from the combined primary and secondary offering totaled EUR 110.6 million.

Intercell’s major shareholders following the exercise of the over-allotment option are: Apax Partners (11.6 %), Temasek Holdings (8.1 %), Novartis (6.1 %), TVM Capital (6.0 %) and Kapital & Wert Group (5.7 %). 1.3 % of the shares issued are held by Intercell as treasury stock and 1.8 % are held by the management.  The current free float is 59.3 %.

Intercell has a total of 39,531,897 issued shares of common stock, which includes 518,389 shares of treasury stock.

Not for distribution in the United States, Canada and Japan  This press release does not constitute an offer to sell or the solicitation of an offer to purchase the shares of Intercell AG.  The shares offered in connection with the public offering in Austria have already been placed. The information contained herein is not for publication or distribution in the United States, Canada, Japan or Australia. This press release is not an offer of securities for sale in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), and may not be offered or sold in the United States absent registration under that Securities Act or an available exemption from it. Any offering of securities to be made in the United States will be made by means of an offering circular that may be obtained from Intercell AG and will contain detailed information about the company and management, as well as financial statements. This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This press release is directed at and/or for distribution in the UK only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons being together referred to as "relevant persons").  This press release is directed only at relevant persons.  Any person who is not a relevant person should not act or rely on this press release or any of its contents. Any investment or investment activity to which this press release relates is available only to relevant persons and will be engaged in only with relevant persons.

@@start.t2@@end of announcement                                                 euro adhoc 07.07.2006 06:55:44

ots Originaltext: Intercell AG
Im Internet recherchierbar:

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Börsen:  Wiener Börse AG / official market

Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: